U.S. Healthcare System: Cost, Outcomes, and Reform
This paper analyzes the key shortcomings of the United States healthcare system, arguing that despite leading in innovation, the system delivers poor value for money. It examines the disproportionately high cost of care relative to comparable nations, driven by information asymmetry, profit-taking, and unregulated drug pricing. The paper also evaluates health outcomes, noting that the U.S. ranks poorly among industrialized nations in infant mortality, life expectancy, and adult mortality rates. It further explores perverse incentives — including overprescription of drugs and dependence on emergency care among the uninsured — and concludes by assessing the limited structural reforms offered by the Affordable Care Act.
- Introduction: Overview of U.S. healthcare strengths and systemic flaws
- The Cost of U.S. Healthcare: Why U.S. healthcare costs far exceed other nations
- Healthcare Effectiveness and Outcomes: Poor health rankings despite high spending
- Perverse Incentives in the System: Structural incentives driving overprescription and overuse
- The Affordable Care Act and Its Limits: ACA's partial reforms and remaining coverage gaps
- Conclusion: Systemic failures persist; structural reform still needed
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a clear, logical structure that moves from cost to effectiveness to incentives, building a cumulative argument about systemic failure rather than treating each problem in isolation.
- Grounds claims in specific comparative data — per capita spending figures, international health rankings, and uninsured population estimates — giving the analysis empirical weight.
- Applies economic concepts (information asymmetry, price elasticity of demand, market failure) to healthcare policy, demonstrating interdisciplinary analytical thinking.
- Ends with a memorable analogy ("paying Ferrari prices and getting a Corolla") that synthesizes the paper's thesis accessibly and memorably.
Key academic technique demonstrated
The paper demonstrates effective use of comparative policy analysis: it consistently benchmarks the U.S. system against comparable industrialized nations rather than evaluating it in isolation. This approach makes the critique concrete and evidence-based, avoiding purely normative claims by anchoring them in measurable cross-national differences in cost and outcome data.
Structure breakdown
The paper opens with a broad framing of the U.S. healthcare system's strengths and failures, then dedicates separate sections to cost drivers, health outcomes, and perverse incentives. The conclusion evaluates the ACA's reforms against the structural problems identified, finding them insufficient. Each section builds on the last, culminating in the overarching argument that the system suffers from market failure with little corrective action in sight.
Introduction
At the high end, the U.S. has the best healthcare system in the world, leading the way in terms of innovation and quality of care. The problem is that the distribution of quality — and of care itself — is uneven. There are many problems that emerge when the system is subjected to closer inspection. The U.S. ranks poorly with respect to health outcomes among industrialized nations. Millions of Americans have no, or inadequate, health coverage. The costs associated with the U.S. healthcare system are much higher than in comparable nations. If the quality of care were significantly better, higher costs might be acceptable, but with poor health outcomes, overprescription of antibiotics, and an emphasis on billing rather than patient care, the U.S. healthcare system has more than its fair share of shortcomings. If an optimal healthcare system provides a high standard of care for everyone and delivers value for money, then on that measure the U.S. system is both inefficient and ineffective. This paper highlights some of the key issues.
References
Bloom, G., Standing, H., & Lloyd, R. (2008). Markets, information asymmetry, and health care: Towards new social contracts. Social Science and Medicine, 66(10), 2076–2087.
Grush, L. (2013). U.S. health outcomes far worse than other comparable nations, report finds. Fox News. Retrieved November 24, 2014, from
Klein, E. (2013). 21 graphs that show America's health-care prices are ludicrous. Washington Post. Retrieved November 24, 2014, from http://www.washingtonpost.com/blogs/wonkblog/wp/2013/03/26/21-graphs-that-show-americas-health-care-prices-are-ludicrous/
Mullin, R. (2014). Cost to develop new pharmaceutical drug now exceeds $2.5 billion. Scientific American. Retrieved November 24, 2014, from http://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/
Murray, C., & Frenk, J. (2010). Ranking 37th — measuring the performance of the U.S. healthcare system. New England Journal of Medicine, 362(Jan 2010), 98–99.
Rogers, S. (2012). Healthcare spending around the world, country by country. The Guardian. Retrieved November 24, 2014, from http://www.theguardian.com/news/datablog/2012/jun/30/healthcare-spending-world-country
Smith, J., & Medalia, C. (2014). Health insurance coverage in the United States: 2013. U.S. Census Bureau. Retrieved November 24, 2014.
Sorinenberg, W. (2014). Patient satisfaction is overrated. MedScape. Retrieved November 24, 2014, from http://www.medscape.com/viewarticle/821288
Wayne, A. (2014). Uninsured rate fell after Obamacare, U.S. report confirms. Bloomberg. Retrieved November 24, 2014, from http://www.bloomberg.com/news/2014-09-16/uninsured-rate-fell-after-obamacare-u-s-report-confirms.html
Create your account
Always verify citation format against your institution’s current style guide requirements.